BRPI0514360A - derivados de ácido 2-{-3-'2-(fenil)-oxazol-4-ilmetoximetil-ciclohexilmetóx i}-propiÈnico usado como ligantes de ppar (receptores ativados por proliferador de peroxissoma) para o tratamento de hiperlipidemia e diabetes - Google Patents
derivados de ácido 2-{-3-'2-(fenil)-oxazol-4-ilmetoximetil-ciclohexilmetóx i}-propiÈnico usado como ligantes de ppar (receptores ativados por proliferador de peroxissoma) para o tratamento de hiperlipidemia e diabetesInfo
- Publication number
- BRPI0514360A BRPI0514360A BRPI0514360-8A BRPI0514360A BRPI0514360A BR PI0514360 A BRPI0514360 A BR PI0514360A BR PI0514360 A BRPI0514360 A BR PI0514360A BR PI0514360 A BRPI0514360 A BR PI0514360A
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- alkyl
- ppar
- oxazol
- acid derivatives
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 101150014691 PPARA gene Proteins 0.000 title 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004039533A DE102004039533B4 (de) | 2004-08-14 | 2004-08-14 | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| PCT/EP2005/008284 WO2006018118A1 (de) | 2004-08-14 | 2005-07-30 | 2-{-3-`2-(phenyl)-oxazol-4-ylmethoxymethyl!-cyclohexylmethoxy}-propionsäure derivate als ppar-liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514360A true BRPI0514360A (pt) | 2008-07-15 |
Family
ID=35376939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514360-8A BRPI0514360A (pt) | 2004-08-14 | 2005-07-30 | derivados de ácido 2-{-3-'2-(fenil)-oxazol-4-ilmetoximetil-ciclohexilmetóx i}-propiÈnico usado como ligantes de ppar (receptores ativados por proliferador de peroxissoma) para o tratamento de hiperlipidemia e diabetes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7538131B2 (https=) |
| EP (1) | EP1789402B1 (https=) |
| JP (1) | JP2008509894A (https=) |
| KR (1) | KR20070046116A (https=) |
| CN (1) | CN101014579A (https=) |
| AR (1) | AR050121A1 (https=) |
| AT (1) | ATE449086T1 (https=) |
| AU (1) | AU2005274495A1 (https=) |
| BR (1) | BRPI0514360A (https=) |
| CA (1) | CA2576584A1 (https=) |
| DE (2) | DE102004039533B4 (https=) |
| DK (1) | DK1789402T3 (https=) |
| ES (1) | ES2335513T3 (https=) |
| IL (1) | IL181011A0 (https=) |
| MX (1) | MX2007000846A (https=) |
| PA (1) | PA8641601A1 (https=) |
| PE (1) | PE20060643A1 (https=) |
| PT (1) | PT1789402E (https=) |
| TW (1) | TW200621733A (https=) |
| UY (1) | UY29064A1 (https=) |
| WO (1) | WO2006018118A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20040199A2 (en) * | 2001-08-31 | 2005-04-30 | Aventis Pharma Deutschland Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
-
2004
- 2004-08-14 DE DE102004039533A patent/DE102004039533B4/de not_active Expired - Fee Related
-
2005
- 2005-07-30 KR KR1020077003579A patent/KR20070046116A/ko not_active Withdrawn
- 2005-07-30 DK DK05772372.8T patent/DK1789402T3/da active
- 2005-07-30 BR BRPI0514360-8A patent/BRPI0514360A/pt not_active IP Right Cessation
- 2005-07-30 AT AT05772372T patent/ATE449086T1/de not_active IP Right Cessation
- 2005-07-30 EP EP05772372A patent/EP1789402B1/de not_active Expired - Lifetime
- 2005-07-30 AU AU2005274495A patent/AU2005274495A1/en not_active Abandoned
- 2005-07-30 PT PT05772372T patent/PT1789402E/pt unknown
- 2005-07-30 ES ES05772372T patent/ES2335513T3/es not_active Expired - Lifetime
- 2005-07-30 CN CNA2005800271483A patent/CN101014579A/zh active Pending
- 2005-07-30 MX MX2007000846A patent/MX2007000846A/es active IP Right Grant
- 2005-07-30 CA CA002576584A patent/CA2576584A1/en not_active Abandoned
- 2005-07-30 DE DE502005008552T patent/DE502005008552D1/de not_active Expired - Lifetime
- 2005-07-30 WO PCT/EP2005/008284 patent/WO2006018118A1/de not_active Ceased
- 2005-07-30 JP JP2007525218A patent/JP2008509894A/ja not_active Abandoned
- 2005-08-10 PE PE2005000925A patent/PE20060643A1/es not_active Application Discontinuation
- 2005-08-11 TW TW094127241A patent/TW200621733A/zh unknown
- 2005-08-11 AR ARP050103350A patent/AR050121A1/es not_active Application Discontinuation
- 2005-08-12 PA PA20058641601A patent/PA8641601A1/es unknown
- 2005-08-12 UY UY29064A patent/UY29064A1/es unknown
-
2007
- 2007-01-28 IL IL181011A patent/IL181011A0/en unknown
- 2007-02-02 US US11/670,594 patent/US7538131B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007000846A (es) | 2007-04-17 |
| WO2006018118A1 (de) | 2006-02-23 |
| AU2005274495A1 (en) | 2006-02-23 |
| ES2335513T3 (es) | 2010-03-29 |
| KR20070046116A (ko) | 2007-05-02 |
| ATE449086T1 (de) | 2009-12-15 |
| UY29064A1 (es) | 2006-02-24 |
| US7538131B2 (en) | 2009-05-26 |
| DE102004039533B4 (de) | 2006-09-28 |
| PT1789402E (pt) | 2010-02-01 |
| WO2006018118A8 (de) | 2006-05-18 |
| DE502005008552D1 (de) | 2009-12-31 |
| US20070197612A1 (en) | 2007-08-23 |
| CA2576584A1 (en) | 2006-02-23 |
| DE102004039533A1 (de) | 2006-03-02 |
| DK1789402T3 (da) | 2010-03-22 |
| TW200621733A (en) | 2006-07-01 |
| CN101014579A (zh) | 2007-08-08 |
| JP2008509894A (ja) | 2008-04-03 |
| AR050121A1 (es) | 2006-09-27 |
| PE20060643A1 (es) | 2006-07-26 |
| IL181011A0 (en) | 2007-07-04 |
| EP1789402A1 (de) | 2007-05-30 |
| PA8641601A1 (es) | 2006-03-24 |
| EP1789402B1 (de) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
| PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
| PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
| BRPI0517803A (pt) | pirazolpirimidinas 1,4-substituìdas como inibidores de cinase | |
| EA200901512A1 (ru) | Агонисты фарнезоидных х-рецепторов | |
| BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| AR035631A1 (es) | Compuestos quimicos | |
| EA200901662A1 (ru) | Агонисты фарнезоидного х-рецептора | |
| EA200801426A1 (ru) | ПРОИЗВОДНЫЕ 2-АДАМАНТИЛМОЧЕВИНЫ В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ 11β-HSD1 | |
| CY1112398T1 (el) | Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1 | |
| CY1109842T1 (el) | Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i | |
| MA31685B1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| PE20080834A1 (es) | Derivados de eter diarilico antagonistas de receptores opioides | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| DK1470102T3 (da) | Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS) | |
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| BRPI0407814A (pt) | derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose | |
| BR0313377A (pt) | Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b | |
| BRPI0416238A (pt) | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) | |
| EA201000926A1 (ru) | Пиперазины в качестве агентов против ожирения | |
| EA200970506A1 (ru) | Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы | |
| BRPI0514360A (pt) | derivados de ácido 2-{-3-'2-(fenil)-oxazol-4-ilmetoximetil-ciclohexilmetóx i}-propiÈnico usado como ligantes de ppar (receptores ativados por proliferador de peroxissoma) para o tratamento de hiperlipidemia e diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE. |